Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics (SAGE) PT Lowered to $90 at Wedbush, Following Earnings
May 4, 2021 11:32 AM EDTWedbush analyst Laura Chico lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $98.00) while maintaining a Outperform rating.
... MoreSage Therapeutics (SAGE) PT Raised to $189 at Goldman Sachs, Following Earnings
May 4, 2021 11:11 AM EDTGoldman Sachs analyst Salveen Richter raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $189.00 (from $187.00) while maintaining a Buy rating.
... MoreSAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss
May 4, 2021 7:16 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.64), $0.27 better than the analyst estimate of ($1.91). Revenue for the quarter came in at $1.58 million versus the consensus estimate of $2 million.
Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises,... More
